Defensive blue chips rarely dominate headlines, but heading into 2027, three of the market’s most reliable dividend payers stand out as durable compounders.
With consumer sentiment at recessionary levels of 49.5 and shoppers trading down, staples and healthcare names are gaining relevance. Let’s walk through how Procter & Gamble (NYSE:PG | PG Price Prediction), Johnson & Johnson (NYSE:JNJ), and Coca-Cola (NYSE:KO) could reach $180, $300, and $100 respectively in 2027.
Where Wall Street Sees These Names Today
PG trades at $146.97, up 4.8% year-to-date, with analysts targeting $160.70. JNJ is a 2026 outperformer, climbing 25.56% year-to-date to $256.98, with the Street eyeing $271.73. KO has done even better, gaining 25.9% YTD to $86.85, with a consensus target of $94.70. Our targets sit above each consensus.
Procter & Gamble: The Path to $180
PG trades near 22x earnings, in line with the market. At $180, that multiple would stretch to roughly 26x FY2027 guidance midpoint of $7, a premium justified by 70 consecutive years of dividend increases. FY2026 delivered revenue of $87.03B (+3.26%) and free cash flow of $15.84B (+12.74%).
CEO Shailesh Jejurikar told shareowners PG is “building momentum with consumers” and is “confident in our plans to accelerate growth from semester-to-semester.”
With Beauty growing 6% in Q4, a 5th consecutive EPS beat, and insider buying, a re-rating toward $180 is achievable if the promised productivity program offsets the $1B commodity headwind.
Johnson & Johnson: The Path to $300
JNJ needs roughly 17% more upside to hit $300. Management raised FY2026 guidance to $100.3B-$101.3B revenue and adjusted EPS of $11.45-$11.65. At $300, JNJ would trade around 26x that midpoint, reasonable for a company posting 9.9% Q1 revenue growth.
Oncology is the engine: DARZALEX grew 22.5%, TREMFYA jumped 68.3%, and RYBREVANT/LAZCLUZE surged 82.7%. CEO Joaquin Duato called 2025 “a catapult year” with the strongest pipeline in company history.
Add 64 straight dividend hikes, the planned Orthopaedics spin-off, and the December 8, 2026 Enterprise Business Review as catalysts.
Coca-Cola: The Path to $100
KO carries a P/E of 26, and $100 would push that toward 29x, a premium the growth profile supports. Management raised guidance for organic revenue growth of 5% and comparable EPS growth of 9%-10%. Q2 volumes rose 5% globally, with Coca-Cola Zero Sugar up 16% and Latin America revenue up 16%. Operating margin expanded to 34.9%.
New CEO Henrique Braun said the company “leveraged our powerful brands and system to gain value share.” The FIFA World Cup 2026 campaign across 180+ markets with 60B digital impressions is a rare demand catalyst. Five straight EPS beats and 19 buy ratings versus 1 sell reinforce the bull thesis.
The Bottom Line on $180, $300, and $100
All three names are defensive, but each has a distinct catalyst: PG’s productivity plan, JNJ’s oncology pipeline, and KO’s World Cup activation.
Healthcare spending rose $203.3B year-over-year to $3,741.0B, and nondurable goods spending climbed $271.2B, tailwinds directly benefiting this trio.
Returns of 15% to 22% on defensive giants shouldn’t be expected annually, but with raised guidance, beat streaks, and macro conditions favoring staples, we’ve outlined the blueprint for PG, JNJ, and KO to surprise investors in 2027.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks